Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05432596 · ClinicalTrials.gov registry record · Phase 2
Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis
A Phase 2 study, sponsored by Aclaris Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 250
- Enrollment target
NCT05432596 is a Phase 2 study that has completed, run by Aclaris Therapeutics. The registered enrollment target is 250 participants.
The verdict
NCT05432596, a Phase 2 study, has completed, sponsored by Aclaris Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and efficacy of ATI-1777 in patients 12 to 65 years old with mild to severe Atopic Dermatitis. Eligible participants will apply either ATI-1777 or Vehicle Topical Solution once daily or twice daily for 4 weeks.
Interventions
- DRUG Vehicle
- DRUG ATI-1777 2.0% w/w
- DRUG ATI-1777 1.0% w/w
- DRUG ATI-1777 0.5% w/w
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2022-05-11 |
| Est. Completion | 2023-11-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05432596
The ClinicalTrials.gov registry entry for NCT05432596 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aclaris Therapeutics, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Vehicle is the first listed.
NCT05432596 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05432596 about?
NCT05432596 is a clinical study titled "Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic Dermatitis". This is a Phase 2b study to determine the safety, tolerability, pharmacokinetic (PK), and efficacy of ATI-1777 in patients 12 to 65 years old with mild to severe Atopic Dermatitis. Eligible participants will apply either ATI-1777 or Vehicle Topical Solution once daily or twice daily for 4 weeks.
What is the current status of trial NCT05432596?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2022-05-11. Estimated completion is 2023-11-14.
What interventions are being tested in trial NCT05432596?
The interventions under investigation include: Vehicle (DRUG), ATI-1777 2.0% w/w (DRUG), ATI-1777 1.0% w/w (DRUG), ATI-1777 0.5% w/w (DRUG).
Who is sponsoring clinical trial NCT05432596?
This trial is sponsored by Aclaris Therapeutics, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.